XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling. Moia R, Terzi di Bergamo L, Talotta D, Bomben R, et al. Br J Haematol 2023;203:416-425.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Moia R, Terzi di Bergamo L, Talotta D, Bomben R, et al. XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling. Br J Haematol 2023;203:416-425.
PMID: 37580908